

## Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Patrick H. Nachman, M.D.

Committee: Circulatory System Devices Panel of the Medical Devices Advisory Committee

Meeting Dates: August 22-23, 2023

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda items on August 22, 2023 to discuss, make recommendations, and vote on information regarding a premarket approval application (PMA) for the ReCor Paradise Ultrasound Renal Denervation System by Recor, Inc., a unit of Otsuka Holdings Co., Ltd. and on August 23, 2023 to discuss, make recommendations, and vote on information regarding the PMA for the Medtronic Symplicity Spyral Renal Denervation System by Medtronic, Inc., I may be considered for participation in the advisory committee meeting described above.

Type of Interest	<u>Nature</u>	Magnitude
I. Personal/Immediate Family		
None		
II. Other Imputed Interests		
Imputed. SGE serves as an uncompensated Councilor at Large (Member of Board of Directors) with fiduciary responsibility, for a Professional Society.	The Professional Society received contributions for general purposes from an unaffected unit of the parent firm of the PMA sponsor for Day 1 and parent of a competing firm to the PMA sponsor on Day 2.	Amount from January 2022 to date is between \$1,000,000 and \$1,500,000
	The Professional Society received contributions for general purposes from the PMA sponsor for Day 2 and a competing firm to the PMA sponsor on Day 1.	Amount from January 2022 to date, is between \$100,000 and \$200,000

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver		
allowing me to participate in the meeting described above. I understand that without public disclosure of these		
interests, I will not participate in the advisory committee meeting described above.		

/ <u>S/</u>	July 24, 2023
Signature	Date